Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis

Abstract Cases of seroconversion on pre-exposure prophylaxis (PrEP) should be carefully investigated, given their public health implications and rarity. We report a case of transmitted drug resistance causing seroconversion on PrEP in spite of high adherence, confirmed with dried blood spot and segm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2021-06, Vol.72 (11), p.2025-2028
Hauptverfasser:	Spinelli, Matthew A, Lowery, Brentton, Shuford, Jennifer A, Spindler, Jon, Kearney, Mary F, McFarlane, Jenny R, McDonald, Cheryl, Okochi, Hideaki, Phung, Nhi, Kuncze, Karen, Jee, Kathryn, Johannessen, DeeJay, Anderson, Peter L, Smith, Dawn K, Defechereux, Patricia, Grant, Robert M, Gandhi, Monica
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - therapeutic use Brief Reports Emtricitabine - therapeutic use HIV HIV Infections - drug therapy Humans Medication Adherence Pharmaceutical Preparations Pre-Exposure Prophylaxis Seroconversion Tenofovir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Cases of seroconversion on pre-exposure prophylaxis (PrEP) should be carefully investigated, given their public health implications and rarity. We report a case of transmitted drug resistance causing seroconversion on PrEP in spite of high adherence, confirmed with dried blood spot and segmental hair drug-level testing and single-genome sequencing.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciaa1011